Symbols / AZTR
AZTR Chart
About
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.92M |
| Enterprise Value | 889.80K | Income | -11.11M | Sales | — |
| Book/sh | 0.41 | Cash/sh | 0.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.34 | PEG | — |
| P/S | inf | P/B | 0.44 | P/C | — |
| EV/EBITDA | -0.08 | EV/Sales | — | Quick Ratio | 0.79 |
| Current Ratio | 1.24 | Debt/Eq | 21.92 | LT Debt/Eq | — |
| EPS (ttm) | -1.47 | EPS next Y | -0.52 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 17:00 | ROA | -99.22% |
| ROE | -215.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.74M |
| Shs Float | 10.19M | Short Float | 3.56% | Short Ratio | 0.27 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.15 |
| Beta | -1.59 | Avg Volume | 1.14M | Volume | 196.72K |
| Target Price | $2.70 | Recom | None | Prev Close | $0.18 |
| Price | $0.18 | Change | 1.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.70
Mean price target
2. Current target
$0.18
Latest analyst target
3. DCF / Fair value
$-10.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.18
Low
$2.00
High
$3.40
Mean
$2.70
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-24 | main | Maxim Group | Buy → Buy | $4 |
- MD Anderson joins test of skin therapy to keep cancer patients on EGFR drugs - Stock Titan ue, 24 Feb 2026 13
- Why Is Azitra (AZTR) Stock Soaring Today - Yahoo Finance Wed, 27 Aug 2025 07
- Azitra Reschedules Special Meeting to Approve Share Issuance - The Globe and Mail Sat, 07 Feb 2026 08
- Azitra, Inc. Announces Reverse Stock Split - PR Newswire Mon, 11 Aug 2025 07
- Azitra, Inc. to Present at BIO Investment & Growth Summit - Finviz hu, 19 Feb 2026 13
- Azitra (NYSE: AZTR) Announces $1.5M Private Placement with Warrants at $0.32 - Stock Titan Mon, 24 Nov 2025 08
- Azitra stock soars after positive preclinical data for ichthyosis treatment - Investing.com Mon, 20 Oct 2025 07
- What analysts say about AZTR stock - Weekly Loss Report & Free High Accuracy Swing Entry Alerts - mfd.ru Sat, 21 Feb 2026 11
- Azitra Shares Soar Pre-Market: What’s Driving The Surge? - Stocktwits Mon, 20 Oct 2025 12
- Azitra to implement 1-for-6.66 reverse stock split - MSN Mon, 11 Aug 2025 20
- Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting - Finviz Fri, 06 Feb 2026 08
- Azitra Inc Compliance Plan Approved by NYSE American - The Globe and Mail hu, 18 Dec 2025 08
- AZTR: Second Quarter Update - Yahoo Finance Mon, 25 Aug 2025 07
- Azitra (NYSE American: AZTR) says $44M registered direct offering report is false - Stock Titan Fri, 07 Nov 2025 08
- Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail Fri, 26 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 47600 | 10034 | — | Purchase at price 0.21 per share. | STASKEY NORM | Chief Financial Officer | — | 2024-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 847.16K | 7.34K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.53M | -10.71M | -10.02M | -9.02M |
| TotalUnusualItems | 4.03M | 34.93K | 0.00 | 232.51K |
| TotalUnusualItemsExcludingGoodwill | 4.03M | 34.93K | 0.00 | 232.51K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.97M | -11.28M | -10.68M | -8.94M |
| ReconciledDepreciation | 448.24K | 425.55K | 405.98K | 84.77K |
| EBITDA | -8.50M | -10.67M | -10.02M | -8.79M |
| EBIT | -8.95M | -11.10M | -10.43M | -8.87M |
| NetInterestIncome | 110.39K | -166.15K | -247.07K | -58.21K |
| InterestExpense | 12.16K | 167.73K | 251.89K | 66.97K |
| InterestIncome | 122.55K | 1.58K | 4.82K | 8.76K |
| NormalizedIncome | -12.15M | -11.31M | -10.68M | -9.17M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.97M | -11.28M | -10.68M | -8.94M |
| TotalExpenses | 10.99M | 8.14M | 9.74M | 9.33M |
| TotalOperatingIncomeAsReported | -10.99M | -7.45M | -9.45M | -9.22M |
| DilutedAverageShares | 568.24K | 34.51K | 60.49K | 60.49K |
| BasicAverageShares | 568.24K | 34.51K | 60.49K | 60.49K |
| DilutedEPS | -15.78 | -366.17 | -222.33 | -193.55 |
| BasicEPS | -15.78 | -366.17 | -222.33 | -193.55 |
| DilutedNIAvailtoComStockholders | -8.97M | -12.64M | -13.45M | -11.71M |
| NetIncomeCommonStockholders | -8.97M | -12.64M | -13.45M | -11.71M |
| PreferredStockDividends | 1.36M | 2.77M | 2.77M | |
| NetIncome | -8.97M | -11.28M | -10.68M | -8.94M |
| NetIncomeIncludingNoncontrollingInterests | -8.97M | -11.28M | -10.68M | -8.94M |
| NetIncomeContinuousOperations | -8.97M | -11.28M | -10.68M | -8.94M |
| TaxProvision | 9.03K | 17.31K | 0.00 | 0.00 |
| PretaxIncome | -8.96M | -11.27M | -10.68M | -8.94M |
| OtherIncomeExpense | 1.92M | -3.65M | -979.69K | 339.99K |
| OtherNonOperatingIncomeExpenses | -2.12M | -3.68M | -979.69K | 107.48K |
| SpecialIncomeCharges | 0.00 | 232.51K | ||
| OtherSpecialCharges | -232.51K | |||
| GainOnSaleOfSecurity | 4.03M | 34.93K | ||
| NetNonOperatingInterestIncomeExpense | 110.39K | -166.15K | -247.07K | -58.21K |
| InterestExpenseNonOperating | 12.16K | 167.73K | 251.89K | 66.97K |
| InterestIncomeNonOperating | 122.55K | 1.58K | 4.82K | 8.76K |
| OperatingIncome | -10.99M | -7.45M | -9.45M | -9.22M |
| OperatingExpense | 10.99M | 8.14M | 9.74M | 9.33M |
| ResearchAndDevelopment | 4.72M | 3.64M | 6.10M | 5.38M |
| SellingGeneralAndAdministration | 6.27M | 4.49M | 3.64M | 3.95M |
| GeneralAndAdministrativeExpense | 6.27M | 4.49M | 3.64M | 3.95M |
| OtherGandA | 6.27M | 4.49M | 3.64M | 3.95M |
| TotalRevenue | 7.50K | 686.00K | 284.00K | 110.00K |
| OperatingRevenue | 7.50K | 686.00K | 284.00K | 110.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.15M | 60.55K | 60.49K | 60.49K |
| ShareIssued | 1.15M | 60.55K | 60.49K | 60.49K |
| NetDebt | 3.11M | |||
| TotalDebt | 555.51K | 885.95K | 7.73M | 992.02K |
| TangibleBookValue | 5.45M | 2.70M | -36.48M | -25.86M |
| InvestedCapital | 5.70M | 2.91M | -29.66M | -24.77M |
| WorkingCapital | 3.85M | 932.38K | 1.91M | 7.28M |
| NetTangibleAssets | 5.45M | 2.70M | -36.48M | -25.86M |
| CapitalLeaseObligations | 555.51K | 885.95K | 1.13M | 0.00 |
| CommonStockEquity | 5.70M | 2.91M | -36.26M | -25.77M |
| TotalCapitalization | 5.70M | 2.91M | -29.66M | -24.77M |
| TotalEquityGrossMinorityInterest | 5.70M | 2.91M | -36.26M | -25.77M |
| StockholdersEquity | 5.70M | 2.91M | -36.26M | -25.77M |
| RetainedEarnings | -57.57M | -48.60M | -37.31M | -26.63M |
| AdditionalPaidInCapital | 63.26M | 51.51M | 1.05M | 868.16K |
| CapitalStock | 763.00 | 40.00 | 104.00 | 104.00 |
| CommonStock | 763.00 | 40.00 | 104.00 | 104.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 1.66M | 2.20M | 43.43M | 35.97M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 284.65K | 599.14K | 41.21M | 34.76M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 33.69M | 33.69M | |
| DerivativeProductLiabilities | 381.00 | 35.45K | 70.28K | 71.10K |
| LongTermDebtAndCapitalLeaseObligation | 284.27K | 563.69K | 7.44M | 992.02K |
| LongTermCapitalLeaseObligation | 284.27K | 563.69K | 840.90K | 0.00 |
| LongTermDebt | 6.60M | 992.02K | ||
| CurrentLiabilities | 1.38M | 1.60M | 2.22M | 1.21M |
| CurrentDeferredLiabilities | 0.00 | 156.00K | 15.00K | |
| CurrentDeferredRevenue | 0.00 | 156.00K | 15.00K | |
| CurrentDebtAndCapitalLeaseObligation | 271.24K | 322.25K | 287.38K | |
| CurrentCapitalLeaseObligation | 271.24K | 322.25K | 287.38K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 32.97K | 31.07K | 27.08K | 43.47K |
| PayablesAndAccruedExpenses | 1.07M | 1.25M | 1.75M | 1.15M |
| CurrentAccruedExpenses | 569.82K | 352.59K | 966.88K | 432.01K |
| InterestPayable | 0.00 | 223.79K | 59.18K | |
| Payables | 501.83K | 897.27K | 784.69K | 719.10K |
| TotalTaxPayable | 11.57K | 0.00 | 0.00 | 1.30K |
| IncomeTaxPayable | 11.57K | 0.00 | 0.00 | 1.30K |
| AccountsPayable | 490.25K | 897.27K | 784.69K | 717.80K |
| TotalAssets | 7.36M | 5.12M | 7.17M | 10.20M |
| TotalNonCurrentAssets | 2.13M | 2.58M | 3.03M | 1.71M |
| OtherNonCurrentAssets | 46.94K | 47.76K | 47.51K | 48.20K |
| NonCurrentDeferredAssets | 631.28K | 742.23K | 800.83K | 620.03K |
| GoodwillAndOtherIntangibleAssets | 246.42K | 210.88K | 219.57K | 97.69K |
| OtherIntangibleAssets | 246.42K | 210.88K | 219.57K | 97.69K |
| NetPPE | 1.21M | 1.58M | 1.96M | 946.68K |
| AccumulatedDepreciation | -515.00K | -401.99K | -286.55K | -168.98K |
| GrossPPE | 1.72M | 1.98M | 2.25M | 1.12M |
| Leases | 28.86K | 28.86K | 28.86K | 28.86K |
| OtherProperties | 1.62M | 1.88M | 2.15M | 1.02M |
| MachineryFurnitureEquipment | 55.14K | 55.14K | 55.14K | 55.14K |
| BuildingsAndImprovements | 14.93K | 14.93K | 14.93K | 14.93K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.23M | 2.54M | 4.14M | 8.49M |
| CurrentDeferredAssets | 4.11K | 67.86K | 216.89K | 0.00 |
| PrepaidAssets | 567.57K | 448.26K | 160.13K | 110.29K |
| Receivables | 101.90K | 223.47K | 266.21K | 334.18K |
| TaxesReceivable | 101.66K | 125.22K | 83.39K | 173.31K |
| AccountsReceivable | 233.00 | 98.25K | 182.82K | 160.87K |
| CashCashEquivalentsAndShortTermInvestments | 4.55M | 1.80M | 3.49M | 8.04M |
| CashAndCashEquivalents | 4.55M | 1.80M | 3.49M | 8.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.56M | -7.68M | -8.69M | -8.72M |
| RepaymentOfDebt | -14.60K | -7.39K | 0.00 | |
| IssuanceOfDebt | 0.00 | 4.35M | 984.39K | |
| IssuanceOfCapitalStock | 13.35M | 5.99M | 0.00 | |
| CapitalExpenditure | -379.25K | -318.26K | -341.01K | -652.27K |
| EndCashPosition | 4.55M | 1.80M | 3.49M | 8.04M |
| BeginningCashPosition | 1.80M | 3.49M | 8.04M | 15.77M |
| ChangesInCash | 2.76M | -1.70M | -4.55M | -7.73M |
| FinancingCashFlow | 13.32M | 5.98M | 4.13M | 992.86K |
| CashFlowFromContinuingFinancingActivities | 13.32M | 5.98M | 4.13M | 992.86K |
| NetOtherFinancingCharges | -37.48K | -216.89K | ||
| ProceedsFromStockOptionExercised | 19.10K | 0.00 | 1.51K | 8.47K |
| NetCommonStockIssuance | 13.35M | 5.99M | 0.00 | |
| CommonStockIssuance | 13.35M | 5.99M | 0.00 | |
| NetIssuancePaymentsOfDebt | -14.60K | -7.39K | 4.35M | 984.39K |
| NetLongTermDebtIssuance | -14.60K | -7.39K | 4.35M | 984.39K |
| LongTermDebtPayments | -14.60K | -7.39K | 0.00 | |
| LongTermDebtIssuance | 0.00 | 4.35M | 984.39K | |
| InvestingCashFlow | -379.25K | -318.26K | -336.76K | -652.27K |
| CashFlowFromContinuingInvestingActivities | -379.25K | -318.26K | -336.76K | -652.27K |
| NetOtherInvestingChanges | -180.80K | -196.27K | ||
| NetIntangiblesPurchaseAndSale | -127.11K | -9.87K | ||
| PurchaseOfIntangibles | -127.11K | -9.87K | ||
| NetPPEPurchaseAndSale | -8.57K | -26.54K | -28.85K | -446.14K |
| SaleOfPPE | 0.00 | 4.25K | 0.00 | |
| PurchaseOfPPE | -8.57K | -26.54K | -33.10K | -446.14K |
| CapitalExpenditureReported | -370.68K | -291.71K | -307.91K | -206.14K |
| OperatingCashFlow | -10.18M | -7.36M | -8.35M | -8.07M |
| CashFlowFromContinuingOperatingActivities | -10.18M | -7.36M | -8.35M | -8.07M |
| ChangeInWorkingCapital | -441.72K | -753.43K | 310.76K | 646.35K |
| ChangeInOtherWorkingCapital | -156.00K | 141.00K | 15.00K | |
| ChangeInOtherCurrentLiabilities | -315.84K | -283.10K | -268.51K | 0.00 |
| ChangeInOtherCurrentAssets | 819.00 | -253.00 | 694.00 | -919.00 |
| ChangeInPayablesAndAccruedExpense | -140.53K | -68.68K | 420.75K | 274.14K |
| ChangeInPayable | -140.53K | -68.68K | 420.75K | 274.14K |
| ChangeInAccountPayable | -140.53K | -68.68K | 420.75K | 282.98K |
| ChangeInTaxPayable | 0.00 | -8.83K | ||
| ChangeInIncomeTaxPayable | 0.00 | -8.83K | ||
| ChangeInPrepaidAssets | -119.31K | -288.12K | -49.84K | 163.95K |
| ChangeInReceivables | 133.15K | 42.73K | 66.67K | 194.17K |
| ChangesInAccountReceivables | 98.02K | 84.56K | -21.95K | -37.57K |
| OtherNonCashItems | 2.13M | 3.80M | 1.42M | 66.81K |
| StockBasedCompensation | 245.05K | 151.50K | 184.47K | 306.06K |
| AssetImpairmentCharge | 442.79K | 351.36K | 0.00 | |
| DepreciationAmortizationDepletion | 448.24K | 425.55K | 405.98K | 84.77K |
| DepreciationAndAmortization | 448.24K | 425.55K | 405.98K | 84.77K |
| AmortizationCashFlow | 11.16K | 7.64K | ||
| AmortizationOfIntangibles | 11.16K | 7.64K | ||
| Depreciation | 437.07K | 417.91K | 405.98K | 84.77K |
| OperatingGainsLosses | -4.04M | -49.70K | 7.10K | -231.67K |
| GainLossOnInvestmentSecurities | -4.03M | -34.83K | -821.00 | -989.00 |
| NetForeignCurrencyExchangeGainLoss | -14.20K | 0.00 | ||
| GainLossOnSaleOfPPE | 4.86K | 41.42K | 7.92K | 0.00 |
| NetIncomeFromContinuingOperations | -8.97M | -11.28M | -10.68M | -8.94M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AZTR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|